Bayer shares rose about 5% on Tuesday after the company raised its 2026 profit outlook on the back of a strong quarter in pharmaceuticals. Third-quarter EBITDA before special items of €1.62bn was about 13% above analysts' expectations. The gain extends a 15.01% rally last week, when a US jury found for Bayer's Monsanto unit in the first Roundup trial since a Supreme Court ruling in June.
The shares were trading about 5% higher by 10:44 GMT, according to Reuters. They closed last week at €50.58, up from €43.98 a week earlier, the second-best weekly gain among tracked stocks.
Bayer, third quarter
- +15.01% shares, week to 30 October
- €1.62bn EBITDA before special items, up 6.9%
- +58% Nubeqa sales, to about €1bn
A Jury Verdict Started the Run
The rally began with a court win. On 29 October a St. Louis County jury returned a unanimous verdict for Monsanto on all claims brought by three plaintiffs in the Aretino case.
It was the first Roundup trial since the US Supreme Court's Durnell decision in June. That ruling held that federal pesticide law overrides state-law failure-to-warn claims where the Environmental Protection Agency has made a definitive safety finding. With those claims gone, the plaintiffs pursued design defect, negligence and fraud claims instead, and lost.
Separately, Bayer wants a $7.25bn settlement to resolve tens of thousands of other Roundup claims. A Missouri state court judge in St. Louis is reviewing it. Chief executive Bill Anderson expects approval before Christmas and said on Tuesday that it could come any week now.
Bayer: share price, chart and news
Pharma Drives the Upgrade
The quarter itself was uneven, but the strong parts were strong. Group sales rose 4.1% to €10.05bn, or 1.9% after currency and portfolio effects, and EBITDA before special items rose 6.9% to €1.615bn.
Pharmaceuticals did most of the work. Sales rose 8% to €4.68bn, about 5% above the Vara Research poll, and the division's EBITDA before special items climbed 23.6% to €1.29bn, a margin of 27.6%. The prostate cancer drug Nubeqa grew 58% to about €1bn in the quarter and the kidney drug Kerendia 65%, both on a currency-adjusted basis. "We've reached a turning point in Pharma's growth trajectory," Anderson said.
Crop Science saw EBITDA before special items fall 41.3% to €101m. Consumer Health slipped 4.4% to €347m.
Below the operating line the picture was weaker. Bayer booked a €307m impairment on the cancer drug Xofigo, and its €407m of net special charges included a €215m impairment on the Claritin allergy brand. The net loss narrowed to €672m from €963m. Core earnings per share fell to €0.31 from €0.49, and free cash flow was negative at €293m, against a positive €596m a year earlier. A MarketScreener analysis put the weak cash flow down mainly to payments linked to the group's legal cases.
The New Targets
| 2026 outlook | New | Previous |
|---|---|---|
| EBITDA before special items (currency-adjusted) | €9.8bn to €10.3bn | €9.6bn to €10.1bn |
| Pharmaceuticals EBITDA margin | 25% to 27% | 23% to 25% |
| Free cash flow | -€1.5bn to -€0.5bn | -€2.5bn to -€1.5bn |
| Net financial debt at year end | €28bn to €29bn | €29bn to €30bn |
Bayer confirmed its other group guidance and now expects pharmaceutical sales toward the top of its range. Net financial debt fell to €31.08bn at the end of September, helped by a €3bn payment from Apollo Global Management for a minority stake in a new entity holding its long-acting contraceptive business.
What Investors Watch Now
Points to watch
- The court decision on the $7.25bn Roundup settlement, which Bayer expects before Christmas.
- Whether the Aretino verdict sets the pattern for later Roundup trials after the Durnell ruling.
- Pharma momentum from Nubeqa and Kerendia, which reduce reliance on older drugs such as Xarelto and Eylea.
- Crop Science, where profit fell sharply, and Consumer Health, where profit slipped.
Union Investment portfolio manager Markus Manns told Reuters that court approval of the settlement would sharply reduce Bayer's litigation risk and let management focus on running the business. After last week's verdict and today's upgrade, that ruling is now the main event for the shares.
Sources
- Chemeurope: Bayer increases sales and EBITDA before special items in the third quarter, improves full-year outlook
- SRN News (Reuters): Bayer hikes 2026 profit outlook as pharma unit beats expectations
- BCLP: BCLP team helps secure defense verdict in first Roundup trial since Supreme Court ruling
- Börse Express: Bayer-Aktie: Glyphosat-Erfolg treibt Kurs
- MarketScreener: Bayer finally sees light at the end of the tunnel
- BMK News market data (delayed exchange data)








